DGAP-News: Nanostart-held Curiox Biosystems wins Emerging Company award
(firmenpresse) - Nanostart AG / Miscellaneous
15.03.2010 07:30
Dissemination of a Corporate News, transmitted by
DGAP - a company of EquityStory AG.
The issuer / publisher is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
- 'Emerging Company of the Year in Asia Pacific' in biomedical sciences
- 'Curiox is a potential industry leader within 10 years'
- Expanding in USA, Europe and Japan
Singapore / Frankfurt - March 15, 2010 - Curiox was awarded 'Emerging
Company of the Year 2010 in Asia Pacific', on 12th March, by BioSpectrum
Asia. BioSpectrum Asia is a leading B2B media platform covering the life
sciences industry in the Asia Pacific region.
Curiox and other Asia Pacific companies were assessed on the basis of their
achievements and potential for future growth to determine companies that
shall emerge as industry leaders, in the biomedical science and
biotechnology sectors, in the coming decade. BioSpectrum's team of industry
experts evaluated all aspects of the organizations' performance and public
profile, prior to nominating Curiox as the winner of the award in the
sector biomedical sciences. The award was given to five more companies from
other sectors in life sciences and medical technologies.
Curiox's 'Emerging Company of the Year' award comes hot on the heels of
Curiox's LabAutomation2010 'Innovation AveNEW' award, earlier this year; as
one of the industry's most innovative laboratory automation technology.
This magnitude of worldwide industry acceptance and excitement for is
welcomed by the young Singaporean start-up Curiox; and comes at a crucial
time as Curiox begins to expand its products to overseas markets.
'It is truly an honour to be selected with top companies in Asia who have
been around much longer than Curiox. These awards demonstrate to our
customers, partners and competitors that our DropArray(TM) technology is
truly innovative, and is recognized by industry experts (on a global scale)
to be beneficial and potentially disruptive to the laboratory automation
industry,' comments Curiox's CEO Dr Namyong Kim.
Curiox's patent-pending DropArray(TM) technology provides a next-generation
'wall-less' microtiter platform, and complimentary washing instrument, to
provide researchers with better quality of data, 10 - 50 times savings in
sample and reagent consumption, and up to 60 % assay time reduction.
Additionally, DropArray(TM) technology promotes integration with liquid
handling systems by maintainaining reproducibility and compatibility with
existing microtiter plate detection systems.
Curiox Biosystems intends to penetrate the United States, European and
Japanese laboratory markets this year through strategic partnerships and
distributors.
According to BioSpectrum Asia, it has a readership of over 150,000
(including print magazine, online-edition and website) of which a large
majority represent key decision makers in the Pharma and Biotech industry.
The Nanostart Singapore Early Stage Venture Fund I holds almost 19% in
Curiox Biosystems.
About Nanostart:
Nanostart AG is the world's leading nanotechnology investment company. The
Frankfurt-based company provides venture capital financing for
nanotechnology companies in various growth phases. It also provides the
benefits of its experience and expertise to developers of financial
instruments and to investors in the nanotechnology sector. For further
information about the company, please visit www.nanostart.de.
About Curiox Biosystems Pte Ltd:
Curiox Biosystems has a vision to accelerate the progress of life sciences
and drug discovery through better miniaturization. Curiox is a
bioinstrumentation company enabling the miniaturization of heterogeneous
bioassay for researchers working in life sciences, drug discovery, and
diagnostics. Curiox's patented miniaturization platform, DropArray(TM),
provides up to 1,000 times savings in sample and reagent consumption, and
up to 10 times reduction in assay time. The company is located in
Singapore, the biomedical hub of Southeast Asia. The company is a spin-off
from Institute of Bioengineering and Nanotechnology (IBN) backed primarily
by Nanostart and Exploit Technologies, the commercializing arm of
Singapore's Agency for Science, Technology and Research (A*STAR). For
further information, please visit www.curiox.com.
Disclaimer:
This notice constitutes neither an offer to sell nor a solicitation of
offers to purchase or subscribe to securities. There will be no public
offering of securities of Nanostart AG in conjunction with the existing
listing of its shares in the 'Entry Standard' segment of the regulated
unofficial market (Freiverkehr) on the Frankfurt Stock Exchange. This
notice does not constitute a securities prospectus. Neither this notice nor
the information contained within is intended for direct or indirect
distribution within the United States of America, Canada, Australia or
Japan.
Media contact:
Nanostart AG
Public Relations
Dr. Hans Joachim Dürr
Goethestrasse 26-28
D-60313 Frankfurt
Germany
phone: +49 (0)69-21 93 96 111
fax: +49 (0)69-21 93 96 122
e-mail: presse(at)nanostart.de
15.03.2010 07:30 Ad hoc announcement, Financial News and Media Release distributed by DGAP. Medienarchiv atwww.dgap-medientreff.deandwww.dgap.de---------------------------------------------------------------------------
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 15.03.2010 - 02:30 Uhr
Sprache: Deutsch
News-ID 1011329
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
Phone:
Kategorie:
Business News
Anmerkungen:
Diese Pressemitteilung wurde bisher 110 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Nanostart-held Curiox Biosystems wins Emerging Company award
"
steht unter der journalistisch-redaktionellen Verantwortung von
Nanostart AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
